Novo Nordisk licenses Merrion's GIPET for oral insulin
This article was originally published in Scrip
Executive Summary
Merrion Pharmaceuticalsand Novo Nordiskhave firmed up their initial collaboration on oral insulin products through a development and commercialisation licensing agreement.